Evaluation of a balloon-based vaginal packing system and patient-controlled analgesia for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy

被引：8

作者：

Xu-Welliver, Meng ^{[1
]}

Lin, Lilie L. ^{[2
]}

机构：

[1] Ohio State Univ, Coll Med, Arthur G James Comprehens Canc Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA

[2] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

PRACTICAL RADIATION ONCOLOGY | 2013年 / 3卷 / 04期

关键词：

D O I：

10.1016/j.prro.2012.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To evaluate the following: (1) the dosimetric impact on the bladder and rectum due to a methodologic shift from general anesthesia (GA) to patient-controlled analgesia (PCA), and from vaginal gauze packing (VGP) to vaginal balloon-based packing (VBP) for high-dose-rate (HDR) intracavitary brachytherapy; and (2) the tolerability of PCA versus GA. Methods and Materials: Seventeen consecutively treated patients with cervical carcinoma who underwent tandem and ovoid (T&O) HDR brachytherapy from January 2009 to August 2010 were selected and reviewed. There were a total of 73 applications. Patients were packed either conventionally with VGP (n = 49) or with VBP (n = 24). Because different sedation methods can influence rectal and bladder dosimetric parameters all applications were grouped by packing method (VBP or VGP) as well as sedation method (GA or PCA). The International Commission on Radiation Units and Measurements (ICRU) and D2cc rectal and bladder doses were obtained from the treatment records and dose-volume histograms, and respective percentage of prescription dose noted and compared. For patients receiving PCA, pain score on a scale of 0-10 was noted. Results: All patients who used PCA were able to tolerate and complete the procedure with a median pain score of 0 (range, 0-2). Implants packed with the VBP method under PCA (n = 21) versus VGP under GA (n = 40) had significantly lower doses to the bladder D2cc (85.7% vs 104.8% of prescription dose), and rectum ICRU dose point (55.4% vs 65.2% of prescription dose), P = .0371 and .039, respectively. The ICRU bladder point and rectum D2cc between the 2 groups were not significantly different. Conclusions: Our results demonstrate that PCA is a feasible method for pain control for T&O brachytherapy. VBP and PCA are compatible with T&O brachytherapy and resulted in comparable if not better bladder and rectal dosimetry. (C) 2013 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

引用

页码：263 / 268

页数：6

共 12 条

[1]

Petereit D.G., Sarkaria J.N., Potter D.M., Schink J.C., High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence-the University of Wisconsin experience, Int J Radiat Oncol Biol Phys, 45, pp. 1267-1274, (1999)

[2]

Hareyama M., Sakata K., Oouchi A., Et al., High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial, Cancer, 94, pp. 117-124, (2002)

[3]

Nag S., Erickson B., Parikh S., Gupta N., Varia M., Glasgow G., The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium, Int J Radiat Oncol Biol Phys, 48, pp. 779-790, (2000)

[4]

Viswanathan A.N., Beriwal S., De Los Santos J.F., Et al., American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy, Brachytherapy, 11, pp. 47-52, (2012)

[5]

Saini A.S., Zhang G.G., Finkelstein S.E., Biagioli M.C., Dose reduction study in vaginal balloon packing filled with contrast for HDR brachytherapy treatment, Int J Radiat Oncol Biol Phys, 80, pp. 1263-1267, (2011)

[6]

ICRU Report 38. Dose and volume specification for reporting intracavitary therapy in gynecology, (1985)

[7]

Potter R., Haie-Meder C., Van Limbergen E., Et al., Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology, Radiother Oncol, 78, pp. 67-77, (2006)

[8]

Stewart A., Bentzen S., Radiobiological aspects of brachytherapy in the era of 3-dimensional imaging, Gynecologic radiation therapy: novel approaches to image-guidance and management, pp. 131-142, (2011)

[9]

Viswanathan A.N., Creutzberg C.L., Craighead P., Et al., International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG), Int J Radiat Oncol Biol Phys, 82, pp. 250-255, (2012)

[10]

Eng T.Y., Fuller C.D., Cavanaugh S.X., Blough M.M., Sadeghi A., Herman T., Significant rectal and bladder dose reduction via utilization of Foley balloon catheters in high-dose-rate tandem and ovoid intracavitary brachytherapy of the uterine cervix, Int J Radiat Oncol Biol Phys, 59, pp. 174-178, (2004)

← 1 2 →